Despite encouraging clinical evidence, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering considerable resistance from pharmacy benefit managers. These insurers https://kaitlynhdkx541830.blue-blogs.com/50289151/company-s-vyndamax-faces-is-encountering-pbm-challenges-the-review-of-reimbursement-fights